Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Healthy
Interventions
DRUG

PF-03463275

Oral single 20 mg dose as two 10mg controlled release tablets

DRUG

PF-03463275

Oral single 40 mg dose as four 10mg controlled release tablets

DRUG

PF-03463275

Oral single 60 mg dose as six 10mg controlled release tablets

DRUG

Placebo

Oral single dose as matching placebo

DRUG

PF-03463275

Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days

DRUG

Placebo

Oral multiple doses as matching placebo for 7 days

Trial Locations (1)

91206

Pfizer Investigational Site, Glendale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY